Question normal

As is discussed in the article, previous study describe score of ≥31, benefited from the addition of chemotherapy, whereas those with a score of less than 18 did not. So this prospective study re-define the low risk group(1-10). In this case what will be the best option for clinicians to offer their patients with score from 11-18? And how about 25-30?